開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
市場消息:諾和諾德Wegovy口服片獲歐盟批准,爲首個口服GLP-1減肥藥。
2026-07-15
市場消息:諾和諾德Wegovy口服片獲歐盟批准,爲首個口服GLP-1減肥藥。
返回
其他消息
2026-07-16
澳元兌美元AUD/USD日內漲幅擴大至0.50%,現報0.7009。
澳元兌美元AUD/USD日內漲幅擴大至0.50%,現報0.7009。
2026-07-15
On July 15 at an online investor Q&A relating to its Sci‑Tech Innovation Board (STAR Market) listing, Changxin Technology vice‑president and board secretary Yuan Yuan said the company has implemented two employee shareholding plans. The first was granted at 1.05 yuan per unit of registered capital, totaling 3,596 person‑times; the second at 0.108 yuan per unit, totaling 3,164 person‑times. The company said the plans establish a long‑term incentive and restraint mechanism to motivate R&D and core
On July 15 at an online investor Q&A relating to its Sci‑Tech Innovation Board (STAR Market) listing, Changxin Technology vice‑president and board secretary Yuan Yuan said the company has implemented two employee shareholding plans. The first was granted at 1.05 yuan per unit of registered capital, totaling 3,596 person‑times; the second at 0.108 yuan per unit, totaling 3,164 person‑times. The company said the plans establish a long‑term incentive and restraint mechanism to motivate R&D and core management, align employee and company long‑term interests, and are expected to have a positive effect on future financial position and operating results.
Chat with us
, powered by
LiveChat